

CERTIFICATE OF MAILING


I hereby certify that this TRANSMITTAL is being deposited with the U.S. Postal Service, with sufficient postage, as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on this 16<sup>th</sup> day of August, 2002.

Typed or Printed name of person signing this certificate:

Wendy A. Frick

Signed: \_\_\_\_\_

*Wendy A. Frick*



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In application of:

Hazen, et al.

Serial No.: 10/039,753

Filed: January 2, 2002

For: **MYELOPEROXIDASE, A RISK  
INDICATOR FOR CARDIOVASCULAR  
DISEASE**

Examiner: Not yet assigned

Art Unit: 3736

Attorney Docket No.: 26473/04177

Assistant Commissioner for Patents  
Washington, D.C. 20231



**24024**

PATENT TRADEMARK OFFICE

**RECEIVED**

SEP 11 2002

TECH CENTER 1600/2900

PATENT

*P#*

**RECEIVED**

AUG 23 2002

TECHNOLOGY CENTER 83700

**TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

Transmitted herewith are the following:

1. Supplemental Information Disclosure Statement;
2. Form PTO-1449;
3. 7 References; and
4. A Return Receipt Postcard.

It is believed that no further fee is required relating to the filing of this Supplemental Information Disclosure Statement. If this is not the case, the Patent Office is hereby authorized to charge any related fee to Deposit Account No. 03-0172. A duplicate copy of this sheet is attached.

Respectfully submitted,

Date: \_\_\_\_\_

*August 16, 2002*

By: \_\_\_\_\_

*Pamela A. Docherty*  
Pamela A. Docherty, Reg. No. 40,591  
(216) 622-8416

CERTIFICATE OF MAILING

I hereby certify that this SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on this 11<sup>th</sup> day of August, 2002.

Typed or Printed name of person signing this certificate:

Wendy A. Frick

Signed: Wendy A. Frick

COPY OF PAPERS  
ORIGINALLY FILED



24024

PATENT TRADEMARK OFFICE

RECEIVED

SEP 11 2002

TECH CENTER 1600/2900

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Hazen, et al.

Serial No.: 10/039,753

Filed: January 2, 2002

For: **MYELOPEROXIDASE, A RISK  
INDICATOR FOR CARDIOVASCULAR  
DISEASE**

) Examiner: Not yet assigned

) Art Unit: 3736

) Attorney Docket No.: 26473/04177

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

AUG 23 2002

TECHNOLOGY CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This information disclosure statement is being filed before the mailing of a first Office Action on the merits. Applicants wish to disclose the following information:

REFERENCES

- ☒ The Applicants wish to make of record the references listed on the attached Form PTO-1449. copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☒ Listed on the attached PTO form 1449 is information known to persons substantively involved in the preparation of the application identified above, and is not a representation that more pertinent information does not exist.
- ☒ The identification of any information herein is not intended to be, and should not be understood as being, an admission that such information, in fact, constitutes "prior art" within the meaning of applicable law. The "prior art" status of any information is a matter to be resolved during prosecution.

**CERTIFICATION**

- ☒ Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this statement.
- ☒ This information disclosure statement is being filed within three months of the filing of the within application and/or **prior to a first Office Action** on the merits being received.

**PETITION**

- ☒ Applicants hereby request consideration of the attached information.

**DEPOSIT ACCOUNT**

- ☐ A check is attached in the amount of \$ \_\_\_\_\_ required under 37 § 1.17(p).
- ☒ It is not believed that any fee is required relating to the filing of this information disclosure statement. If this is not the case, the patent office is hereby authorized to charge any related fee to **Deposit Account No. 03-0172**.

Respectfully submitted,

Date: August 16, 2002

By: Pamela A. Docherty  
Pamela A. Docherty, Reg. No. 40,591  
(216) 622-8416

COPY OF PAPERS  
ORIGINALLY FILED

RECEIVED

SEP 11 2002


Page 1 of 1

TECH CENTER 1600/2900

Subst. Form PTO-1449  APPLICANT'S INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 26473/04177	Serial No.: 10/039,753
	Applicant: Hazen, et al.	
	Filing Date: January 2, 2002	Group: 3736

U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subcl.	Filing Date
	AA	5,122,534	June 16, 1992	Loose, et al.			Jul. 10, 1991
	AB	5,889,042	March 30, 1999	MacLean, et al.			Feb. 21, 1997
	AC						
	AD						



FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Subcl.	Translati n?
AE						
AF						
AG						
AH						
AI						

RECEIVED  
AUG 23 2002

OTHER PRIOR ART

TECHNOLOGY CENTER RST00

AJ	International Search Report dated July 31, 2002.
AK	"Oxidized LDL and HDL: antagonists in atherothrombosis" by Mertens, et al., <u>FASEB J.</u> , 15, 2073-2084 (2001).
AL	"Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species" by Podrez, et al., <u>J. Clin. Invest.</u> 105:1095-1108 (2000).
AM	"Inhibition of Adhesion Molecules Markedly Ameliorates Cytokine-Induced Sustained Myocardial Dysfunction in Dogs <i>in vivo</i> " by Momii, et al., <u>J. Mol. Cell. Cardiol.</u> 30, 2637-2650 (1998).
AN	"Supplementation with Tetrahydrobiopterin Suppresses the Development of Hypertension in Spontaneously Hypertension Rats" by Hong, et al., <u>Hypertension</u> , 2001; 38:1044-1048.
AO	
AP	
AQ	
AR	

Examiner:	Date Considered:
-----------	------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.